Article

Eye Bank Tissue Can Harbor Pathogens

Author(s):

Eye banks are generally thought to be a safe place to get tissue for corneal transplant. But a New Hampshire team reporting at ID Week 2015 in San Diego, CA said they found two post-operative candida infections in corneal transplant recipients .

Eye banks are generally thought to be a safe place to get tissue for corneal transplant. But a New Hampshire team reporting at ID Week 2015 in San Diego, CA said they found two post-operative candida infections in corneal transplant recipients .

James Noble, MD of Concord Hospital, Concord NH and colleagues reported that though cultures of such eye bank donor tissue are rarely performed one surgeon routinely cultured unused corneal rim tissue and discovered the infections.

“An investigation ensued,” he wrote.

That revealed two confirmed cases of fungal keratitis and additionally two corneal rim cultures positive for fungi all in banked corneal tissue from a single tissue bank. They did not identify the bank.

Nine out of 99 routine cultures of eye bank corneal tissue also recovered fungus, for a percentage of 9.1%.

“Surprisingly nearly 1 in 10 coreas from banked donor tissue may be positive for fungal pathogens,” Noble warned in an abstract.

“It is important to consider fungal pathogens in the ifferential diagnosis of post-corneal transplant infections,” he concluded.

Related Videos
Age, Race, Ethnicity Disparities Hinder Celiac Disease Screening, with Debra Silberg, MD, PhD
Lauren Collen, MD: Advanced Combination Therapy May Be Effective Option for Pediatric Refractory IBD
Lauren Collen, MD: Some Fragrances May be More Prevalent in Exposomes of Children with Crohn’s Disease
Impact of Long Hospital Stays on Pediatric Gastroparesis Management with Christian Sadaka, MD
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Implications of Findings on Patient-Reported Outcomes for Roflumilast Foam, with Melinda Gooderham, MD
New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.